Prostascint – pro
Indium In 111 capromab pendetide (ProstaScint®; Cytogen Corporation, Princeton, NJ), a radiolabeled monoclonal antibody to prostate-specific membrane antigen, offers a potential means of localizing sites of soft tissue metastasis in prostate cancer patients. Although the test was previously limited by poor positive predictive value and specificity owing to the inherent limitations of single photon emission computed tomography, improvements in techniques of anatomic localization, along with increased reader experience, have significantly improved its accuracy. However, full potential of the test is not fully known and it remains a subject to investigation and remains experimental.
Ponsky LE, Cherullo EE, Starkey R, et al. Evaluation of preoperative ProstaScint scans in the prediction of nodal disease. Prostate Cancer Prostatic Dis. 2002;5:132–135.
15.Freeman LM, Krynyckyi BR, Li Y, et al. The role of (111)In Capromab Pendetide (Prosta-Scint®) immunoscintigraphy in the management of prostate cancer. Q J Nucl Med. 2002;46:131–137.
Murphy GP, Elgamal AA, Troychak MJ, Kenny GM. Follow-up ProstaScint scans verify detection of occult soft-tissue recurrence after failure of primary prostate cancer therapy. Prostate. 2000;42:315–317.